Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT
- Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT
- Investor call on Monday, November 27, 2023 8:00 a.m. ET
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website. The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.
"MCLA-129 is now the third asset, together with our other clinical assets petosemtamab and zenocutuzumab, developed from the Merus proprietary Biclonics® platform to demonstrate strong clinical activity," said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "As we continue the development of MCLA-129, we are planning to take a disciplined capital allocation approach, making focused investments in the program to identify areas of potential differentiation. We remain open to potential business development opportunities as a means to leverage added resources, infrastructure and expertise of a potential partner to more fully evaluate and develop MCLA-129."
MCLA-129 (EGFR x c-MET Biclonics®): Solid Tumors
Interim data included in the abstracts describe data from three expansion cohorts in the open label trial evaluating MCLA-129 in combination with osimertinib, a third generation EGFR TKI, in treatment-naïve EGFR mutant (m) NSCLC and in EGFRm NSCLC that has progressed on osimertinib, as well as MCLA-129 monotherapy in previously treated HNSCC.
Updated clinical data, with additional patients and a later data cutoff date, will be included in the mini-oral presentation on NSCLC and the poster on HNSCC at ESMO Asia next week.
Mini-oral presentation title: Efficacy and safety of MCLA-129, an EGFR x c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Observations in the abstract include:
Presentation Details:
Session: Thoracic Cancer
Date: Sunday, December 3, 2023
Time: 9:40 -9:45 a.m. SGT
Presentation #: 516MO
Poster presentation title: Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Observations in the abstract include:
Presentation details:
Session Category: Poster session
Date: Saturday, December 2, 2023
Time: 17:50-18:45 p.m. SGT
Presentation #: 362P
MCLA-129 Development Strategy
In EGFRm NSCLC, with the strong clinical activity for MCLA-129 shown in the interim data presented today, we are encouraged by the potential for MCLA-129 in the treatment of lung cancer and beyond. We have identified focused investment opportunities. We continue to follow patients with EGFRm NSCLC treated with MCLA-129 in combination with osimertinib, to evaluate potential for biomarkers as a means to maximize efficacy, while proactively addressing safety signals seen to date.
We plan to start a cohort of MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC in the first quarter of next year.
Additionally, we remain interested and are continuing investigation of cohort B evaluating MCLA-129 in patients with MET exon14 skipping NSCLC. We also remain interested in exploring partnering MCLA-129 with other companies to sufficiently resource the development of MCLA-129 and potential benefit it may have for patients.
In HNSCC, based on the interim data, we observed clinical activity with MCLA-129. However, we view the clinical activity with MCLA-129 monotherapy as of the cutoff date as modest, with 2 unconfirmed partial responses or 17%. The safety profile was manageable, and there were no reported ILD or VTE events. Our assessment of this cohort is that the clinical activity of MCLA-129 in second line head and neck cancer appears substantially inferior to that of our lead asset petosemtamab, and only on par with other EGFR or cetuximab-based monoclonal or bispecific antibodies as monotherapy in a similar setting. We believe this efficacy is insufficient to warrant further development in head and neck cancer.
Zenocutuzumab (Zeno or MCLA-128: HER2 x HER3 Biclonics®): NRG1 fusion (NRG1+) cancer and other solid tumors
An abstract for an encore of a recent ESMO Congress 2023 presentation on zenocutuzumab interim clinical data from the eNRGy trial and Early Access Program in patients with NRG1 fusion (NRG1+) NSCLC has also been accepted for presentation at ESMO Asia.
Presentation details:
Title: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Session Category: Poster session
Date: Saturday, December 2, 2023
Time: 17:50-18:45 p.m. SGT
Presentation #: 595P
As full presentations become available at the ESMO Asia Congress 2023, they will contemporaneously be available on the Merus website.
Company Conference Call and Webcast Information
Merus will hold a conference call and webcast for investors on November 27, 2023 at 8:00 a.m. ET. A replay will be available after the completion of the call in the Investors and Media section of our website for a limited time.
Date and Time: November 27, 2023 at 8:00 a.m. ET
Webcast link: Available on our website
Dial-in: Toll-Free: 1 (800) 715-9871 / International: 1 (646) 307-1963
Conference ID: 2833671
Posted In: MRUS